Sutro Biopharma, Inc. (STRO) Tops Q2 EPS by 27c

Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q2 EPS of ($0.14), $0.27 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $63.74 million versus the consensus estimate of $15.79 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boeing lands two U.S. defense contracts worth over $711M